Validation du 18F-Fluoroethoxybenzovesamicol(FEOBV) comme biomarqueur de la maladie d'Alzheimer.

 

Marc-André Bédard

CUSM - Institut neurologique de Montréal

 

Domaine : Neurosciences, santé mentale et toxicomanies

Fonds d'onnovation Pfizer-FRQS

Concours 2013-2014

This research program has two components. The main one will be about the validation of a method to help diagnose Alzheimer's disease (AD), and follow its progression with time. Such tools are called biomarkers. Those currently known are useful, although not sensitive enough to evaluate AD severity, or to identify AD among other related diseases. Moreover, some of them are far too indirect measures of AD specific biological features.

In the past few years, our team has focused on a potential new AD biomarker, allying positron emission tomography (PET), coupled with the use of a radioactive compound called FEOBV. Our animal studies have shown the reliability and sensitivity of this method to detect lesions of the cholinergic cells in the brain, which is known to characterize AD. The program described here aim at validating in human, the use of FEOBV as a biomarker for AD.

Thirty participants will be included in the study. They will be assessed with FEOBV and two other well known - although imperfect - biomarkers for AD. However, before such a first in human trial, it will be necessary to obtain approval from our regulatory agency, Health Canada. The latter will base its decision on the FEOBV safety. Therefore, the other part of this research program will be focused on the FEOBV safety in two animal species.

At the end of these two studies, FEOBV could become a useful tool in clinical practice, or to evaluate if new curative treatments can slow or reverse the progression of AD.